HURA - NASDAQ

TuHURA Biosciences, Inc.

HURA·NASDAQ

$2.19

+5.8%

HealthcareBiotechnology

TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$139.46M

EPS-0.6300

P/E Ratio-3.48

Earnings Date08/13/2026

hura

Property, Plant, and Equipment (Net)

Last Annual Value

685.17K

3-Year CAGR

18%

5-Year CAGR

36%

10-Year CAGR

Adjust for Inflation

TuHURA Biosciences, Inc. Competitors Analysis of Property, Plant, and Equipment (Net)

HURA · NASDAQ

Company	Property, Plant, and Equipment (Net)	CAGR 3Y	CAGR 5Y	CAGR 10Y
TuHURA Biosciences, Inc. NASDAQ:HURA	685.17K	50.0%	2.1%	N/A
Cognition Therapeutics, Inc. NASDAQ:CGTX	399.00K	-24.9%	22.4%	N/A
Seer, Inc. NASDAQ:SEER	35.24M	-9.4%	1.2%	N/A
Context Therapeutics Inc. NASDAQ:CNTX	140.07K	108.2%	N/A	N/A
Ovid Therapeutics Inc. NASDAQ:OVID	0.00	N/A	N/A	N/A
Armata Pharmaceuticals, Inc. AMEX:ARMP	46.10M	-7.0%	3.9%	45.7%
Inovio Pharmaceuticals, Inc. NASDAQ:INO	9.07M	-14.4%	-20.8%	0.0%
Seres Therapeutics, Inc. NASDAQ:MCRB	80.12M	-9.5%	17.3%	8.3%
Agenus Inc. NASDAQ:AGEN	24.25M	-47.0%	-23.3%	-0.6%
Acumen Pharmaceuticals, Inc. NASDAQ:ABOS	0.00	N/A	N/A	N/A
VistaGen Therapeutics, Inc. NASDAQ:VTGN	1.81M	-13.2%	-12.8%	35.4%

TuHURA Biosciences, Inc. Fair Value Envelope

HURA · NASDAQ

Our analysis suggests that HURA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.19, this represents a potential HIDDEN relative to our calculated worth for TuHURA Biosciences, Inc..

HIDDEN

Intrinsic Value

Current Price: $2.19

Related Guides

Blog Categories

Continue your HURA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.